Banco Bilbao Vizcaya Argentaria S.A. Purchases 167,902 Shares of Moderna, Inc. (NASDAQ:MRNA)

Banco Bilbao Vizcaya Argentaria S.A. increased its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 99.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 337,230 shares of the company's stock after buying an additional 167,902 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. owned about 0.09% of Moderna worth $13,703,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Syon Capital LLC purchased a new stake in Moderna in the 4th quarter worth about $463,000. Symmetry Investments LP bought a new stake in shares of Moderna in the fourth quarter valued at approximately $423,000. Quantessence Capital LLC purchased a new stake in shares of Moderna during the 4th quarter valued at approximately $1,851,000. Alpine Global Management LLC purchased a new position in Moderna in the 4th quarter valued at approximately $224,000. Finally, Massar Capital Management LP bought a new stake in Moderna during the 4th quarter valued at $8,427,000. Institutional investors own 75.33% of the company's stock.

Moderna Stock Up 0.4 %

Shares of MRNA traded up $0.10 during trading hours on Wednesday, hitting $27.92. The company had a trading volume of 2,388,551 shares, compared to its average volume of 7,348,566. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $170.47. The stock's 50 day moving average price is $29.91 and its 200 day moving average price is $38.08. The firm has a market cap of $10.79 billion, a P/E ratio of -3.01 and a beta of 2.23.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on MRNA shares. Leerink Partners reduced their price target on Moderna from $31.00 to $27.00 and set an "underweight" rating for the company in a research report on Thursday, January 16th. Citigroup started coverage on Moderna in a report on Thursday, March 13th. They set a "neutral" rating and a $40.00 target price for the company. Royal Bank of Canada reissued a "sector perform" rating and issued a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. JPMorgan Chase & Co. reduced their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Friday, March 21st. Finally, Evercore ISI set a $50.00 target price on shares of Moderna in a research note on Friday, February 14th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $58.70.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.